MedTrace Logo

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

NCT07297667 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-12

No results posted yet for this study

Summary

Only enrolling in Canada.

The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Conditions

Interventions

DRUG

Fludarabine

Assigned at enrollment

DRUG

Cyclophosphamide

Assigned at enrollment

BIOLOGICAL

GCAR1

Dose escalation

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • BioCanRx

    collaborator UNKNOWN

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Mona Shafey · Tom Baker Cancer Centre, Calgary, Alberta, Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-12-01
Completion
2033-09-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07297667 on ClinicalTrials.gov